MX2020009496A - Metodo para tratar asma o enfermedad alergica. - Google Patents

Metodo para tratar asma o enfermedad alergica.

Info

Publication number
MX2020009496A
MX2020009496A MX2020009496A MX2020009496A MX2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A MX 2020009496 A MX2020009496 A MX 2020009496A
Authority
MX
Mexico
Prior art keywords
allergic disease
treating asthma
agent
notch4
asthma
Prior art date
Application number
MX2020009496A
Other languages
English (en)
Spanish (es)
Inventor
Talal Amine Chatila
Hani Harb
Mingcan Xia
Amir Massoud
Original Assignee
The Children´S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children´S Medical Center Corp filed Critical The Children´S Medical Center Corp
Publication of MX2020009496A publication Critical patent/MX2020009496A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/122Chronic or obstructive airway disorders, e.g. asthma COPD
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020009496A 2018-03-15 2019-03-15 Metodo para tratar asma o enfermedad alergica. MX2020009496A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643476P 2018-03-15 2018-03-15
US201862652630P 2018-04-04 2018-04-04
US201862659379P 2018-04-18 2018-04-18
PCT/US2019/022493 WO2019178488A1 (en) 2018-03-15 2019-03-15 Method for treating asthma or allergic disease

Publications (1)

Publication Number Publication Date
MX2020009496A true MX2020009496A (es) 2021-02-26

Family

ID=67908052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009496A MX2020009496A (es) 2018-03-15 2019-03-15 Metodo para tratar asma o enfermedad alergica.

Country Status (12)

Country Link
US (1) US20210278418A1 (enExample)
EP (1) EP3765025A4 (enExample)
JP (2) JP2021518345A (enExample)
KR (1) KR20200136939A (enExample)
CN (1) CN112188901A (enExample)
AU (1) AU2019236244B2 (enExample)
BR (1) BR112020018810A2 (enExample)
CA (1) CA3094143A1 (enExample)
MX (1) MX2020009496A (enExample)
RU (1) RU2020133768A (enExample)
WO (1) WO2019178488A1 (enExample)
ZA (1) ZA202005720B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230212274A1 (en) * 2020-02-21 2023-07-06 The Children's Medical Center Corporation Method for treating asthma or allergic disease
CA3182210A1 (en) * 2020-06-12 2021-12-16 Talal CHATILA Methods and compositions for treating coronavirus infectious disease
CN116473968A (zh) * 2022-01-24 2023-07-25 华中科技大学 Ezh2特异性抑制剂在治疗哮喘的用途
JP2025533355A (ja) 2022-10-05 2025-10-06 アルシーア セラピューティクス, インコーポレイテッド 気道炎症を処置するためのnotch4抗体、組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2573565A1 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
US20060211079A1 (en) * 2005-02-18 2006-09-21 Hazen Stanley L Systemic markers for asthma and analogous diseases
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
WO2007028110A2 (en) * 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
US10206941B2 (en) * 2013-07-09 2019-02-19 President And Fellows Of Harvard College Venule endothelial cell genes and uses thereof
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
WO2019036613A1 (en) * 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS

Also Published As

Publication number Publication date
EP3765025A1 (en) 2021-01-20
KR20200136939A (ko) 2020-12-08
AU2019236244A1 (en) 2020-10-22
ZA202005720B (en) 2022-01-26
WO2019178488A1 (en) 2019-09-19
JP2024063095A (ja) 2024-05-10
CN112188901A (zh) 2021-01-05
AU2019236244B2 (en) 2025-02-20
BR112020018810A2 (pt) 2021-02-17
US20210278418A1 (en) 2021-09-09
JP2021518345A (ja) 2021-08-02
EP3765025A4 (en) 2022-03-09
CA3094143A1 (en) 2019-09-19
RU2020133768A (ru) 2022-04-15

Similar Documents

Publication Publication Date Title
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
EP4349997A3 (en) Anti-garp antibody
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
MY203971A (en) Anti-lag-3 antibodies and compositions
PH12019501706A1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
EP4316517A3 (en) Combination therapy against cancer
EP4234013A3 (en) Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
WO2018226992A8 (en) Tau aggregation inhibitors
MX2020008122A (es) Anticuerpos anti-pd-1.
HK1254432A1 (zh) 用於治疗纤维性疾病的方法和组合物
EP4445913A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
HK1259083A1 (zh) 用於治疗系统性肥大细胞增多症的方法和组合物
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
NZ762312A (en) Anti-pacap antibody
MX2019009586A (es) Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal.
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof